Related references
Note: Only part of the references are listed.Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis
Philip Mease et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
R. Landewe et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0
Maarten Boers et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2014)
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
Joachim Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis
Jacqueline E. Paramarta et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial
Desiree van der Heijde et al.
RHEUMATOLOGY (2012)
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores
Pedro Machado et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
M. Rudwaleit et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
C. Lukas et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Efficacy and safety of adalimumab in patients with ankylosing spondylitis - Results of a multicenter, randomized, double-blind, placebo-controlled trial
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2006)
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis
J Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy
F Van den Bosch et al.
ARTHRITIS AND RHEUMATISM (2002)
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
PJ Mease et al.
LANCET (2000)
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy:: an open pilot study
F Van den Bosch et al.
ANNALS OF THE RHEUMATIC DISEASES (2000)
Share Paper
